Entero Therapeutics acquires GridAI in share exchange; former GridAI holders to own 82.5% of diluted ENTO

GridAI Technologies Corp.

Acquired 100% of GridAI for 424,348 common shares (19.99% of outstanding) and 38,801,546 Series H convertible shares.
Upon conversion (subject to shareholder approval), former GridAI stockholders will own 82.5% of ENTO on a fully diluted basis.
GridAI is a grid-edge AI platform managing behind-the-meter assets; over $50M invested since 2019.
ENTO must raise at least $3M in gross proceeds within 30 days post-closing and maintain $2M cash minimum.
Former GridAI shareholders get right to designate 2 directors initially, eventually 5 of 7 board seats.

item 1.01 item 2.01 item 3.02 item 5.03 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

GridAI Technologies Corp.: Filed Certificate of Designation creating Series H Preferred Stock (effective 2025-10-01).

Change: charter amendment
Effective: 2025-10-01

Exact text from the filing

On October 1, 2025, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware.

View on SEC.gov

74 governance changes filed in the last 30 days. Browse all governance changes →

GridAI Technologies Corp. filing history →

Source: SEC EDGAR

accession 0001104659-25-097138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.